UK Regulator Calls For More Patient Involvement In Trial Design
More Flexible Rules On GCP And IMPs Are Planned
UK plans for a flexible and streamlined clinical trial regulatory regime are now out for consultation, covering areas such as investigational medicinal products, greater patient involvement in trial design, and lighter-touch oversight of low-intervention trials.
You may also be interested in...
The UK is making progress with framing guidance on meaningful involvement of patients and public in clinical trials.
Research-based drug companies are asking for swift implementation of UK clinical trial reforms to ensure the country does not lose out on commercial trial activity amid challenges such as capacity constraints in the NHS and delays in regulatory approvals.
In this second article on the post-Brexit fortunes of the UK medicines regulator, the MHRA, Pink Sheet looks at the emergence of a new UK clinical trials environment, how the agency is facing up to resource pressures, and when the new fee structure might be ready.